Baker McKenzie acted as legal advisor to ExpreS2ion Biotech Holding in connection with the rights issue.
ExpreS2ion Biotech Holding AB completed a rights issue of units consisting of shares and warrants with preferential rights for ExpreS2ion Biotech Holding’s existing shareholders.
Through the rights issue, ExpreS2ion Biotech Holding will receive approximately SEK 131 million (approx. $15 million) before costs related to the rights issue. Upon full exercise of the warrants, the company will receive additionally up to approximately SEK 85 million before deduction of costs related to the rights issue.
Expres2ion Biotech Holding AB operates as a biotechnology company that is engaged in the research and development of custom proteins, stable protein expression, and transfection reagents.
he Baker McKenzie team consisted of Stefan Balazs (Picture), Ian Gulam, Olof Larsson and Joakim Falkner.
Law Firms: Baker McKenzie;
Clients: ExpreS2ion Biotech Holding;